Our Team

Our Board/management team is comprised of four highly qualified personnel with direct experience of developing and commercialising UK R&D, particularly in the translation of UK science into commercialisable products. They have extensive knowledge and experience of work in the pharmaceutical and biotechnology sectors, biological science, clinical medicine, patenting, commercial law and finance.

The team provide strategic direction and project management to the Company’s activities; all other work is contracted out to third parties.

Prof. John Hermon-Taylor
BA. MB.BChir., MChir., FRCS. Chief Scientific and Medical Officer

John was the Professor and Chairman of Surgery at St George’s Hospital and Medical School from 1976-2002. During this time he ran a specialist service in the clinical management of Inflammatory Bowel Disease, particularly CD. He set up the Molecular Biology Laboratory at St George’s in 1979 and led a research team of young scientists and clinical trainees for 25 years focused on the causation and treatment of CD.

Having retired from the Chair of Surgery in September 2002, John continued the research and development of the anti-MAP vaccine at St George’s. He also jointly held an MRC/NERC five-year grant to study MAP contamination of the environment in rivers, sediments and water supplies as a source of human exposure. In March 2008 John moved to the Gastroenterology group, Division of Diabetes and Nutritional Sciences, King’s College London, where he is a Visiting Professor.

Michael Paynter
LL.B, LL.M, CTA.

Michael is a UK Solicitor and Chartered Tax Advisor and has specialised in commercial tax advice for 30 years. He has a Bachelor of Laws degree from the University of London and a Master of Law degree from the University of Cambridge. He has extensive experience of commercial transactions including company acquisitions, disposals and reconstructions as well as buy-outs and private equity placings.

Michael Stallibrass

Michael was an investment banker in the City for over 30 years (latterly with UBS Warburg where he headed up the European Life Sciences Group). In the last 15 years of his time in the City he specialised in providing strategic, financial and M&A advice to a wide range of pharmaceutical and biotechnology companies in Europe.